Results 91 to 100 of about 4,478 (181)

Spatial transcriptomics reveals clonal relationships between intraductal carcinoma and adjacent invasive prostate cancer

Histopathology, EarlyView.
Spatial transcriptomics of six prostate samples reveals a close clonal relationship between high‐grade Prostatic Intraepithelial Neoplasia (HGPIN), Intraductal carcinoma (IDC) and adjacent invasive glands. In three samples, adjacent invasive glands had more copy number variants than HGPIN and IDC. Adjacent invasive glands were also placed at the end of
Hridya Harikumar, Myrthe de Waard‐van Baardwijk, Marit de Haan, Gregory van Beek, Karishma Lila, Martin E van Royen, Thierry PP van den Bosch, Mathijs A Sanders, Eric Bindels, Andrew Stubbs, Geert JLH van Leenders   +10 more
wiley   +1 more source

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

Prognostic Role of Serum Neuron‐Specific Enolase at Baseline and its Early Dynamics in Metastatic Castration‐Resistant Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors

The Prostate, Volume 86, Issue 11, Page 1187-1194, August 2026.
ABSTRACT Background Outcomes of metastatic castration‐resistant prostate cancer (mCRPC) treated with androgen receptor signaling inhibitors (ARSIs) vary widely and may not be fully reflected by PSA and standard clinicopathologic factors. We evaluated the prognostic value of serum neuron‐specific enolase (NSE) at baseline and early on‐treatment dynamics.
Ondřej Fiala, Michaela Tkadlecová, Zuzana Váchalová, Milan Hora, Jan Králíček, Petr Stránský Jr., Václav Liška, Matteo Santoni, Giuseppe Luigi Banna, Kristýna Pivovarčíková, Ondřej Topolčan, Jindřich Fínek   +11 more
wiley   +1 more source

Unsampled large cribriform and intraductal carcinoma and the limits of risk stratification by prostate biopsy

BJU International, EarlyView.
Mohamad Watfa, Mohammad El Hussein, Salim K. Younis, Kristina Dortche, Rui M. Bernardino, Abdulrahman Al‐Bayati, Betty Wang, Riccardo Autorino, Jesse K. McKenney, Samuel Haywood, Jihad Kaouk, Christopher J. Weight, Jane K. Nguyen, Zeyad R. Schwen   +13 more
wiley   +1 more source

Spatial Distribution of Prostate Cancer Missed by MRI‐Targeted Biopsy, Effect of a Perilesional Template, and Restaging in a Radical Prostatectomy Cohort

The Prostate, Volume 86, Issue 11, Page 1216-1223, August 2026.
ABSTRACT Purpose Systematic biopsy (SB) remains recommended in addition to MRI‐targeted biopsy (TB) because TB alone may miss clinically significant prostate cancer (sPC). We evaluated the spatial distribution of sPC and clinically insignificant prostate cancer (iPC) detected by SB in relation to MRI lesions and assessed the effect of perilesional ...
Ruth Himmelsbach, Julia Franz, Cordula Jilg, Christian Gratzke, August Sigle   +4 more
wiley   +1 more source

Efficacy, Safety, and Cost‐Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non‐Metastatic Castration‐Resistant Prostate Cancer: A Multicenter Retrospective Study

The Prostate, Volume 86, Issue 11, Page 1233-1240, August 2026.
ABSTRACT Background The introduction of novel androgen receptor signaling inhibitors (ARSIs) has substantially transformed the systemic treatment landscape for non‐metastatic castration‐resistant prostate cancer (nmCRPC). Unfortunately, ARSI therapy is associated with considerable adverse events (AEs) and high medical costs.
Himawari Asanuma, Naoki Fujita, Shumon Kato, Yohei Kawashima, Masanao Shinohara, Ryuji Tabata, Fumiya Yoneyama, Ryuma Tanaka, Takuya Oishi, Hikari Miura, Kyo Togashi, Kazutaka Okita, Hirotaka Horiguchi, Toshikazu Tanaka, Daisuke Noro, Yuichiro Suzuki, Satoshi Sato, Chikara Ohyama, Shingo Hatakeyama   +18 more
wiley   +1 more source

Prognostic Factors for Postoperative Complications. An Aggregate Protocol for 10 Observational Studies From the Danish TRIPLE‐A Cohort of 1.2 Million Surgeries

Acta Anaesthesiologica Scandinavica, Volume 70, Issue 7, August 2026.
ABSTRACT Background Postoperative complications substantially increase morbidity, mortality and healthcare costs. Understanding prognostic factors is essential for risk stratification, targeted prevention strategies, and development of prediction models.
Anders Peder Højer Karlsen, Asta Prescott, Caroline Folkersen, Jens Laigaard, Atena Saito, Caroline Lando Klammer, Mik Wetterslev, Emil Ipsen Ørskov, Mathilde Fahrendorff, Rebecca Kiær, Helene Holm Laigaard, Nichlas Hovmand, Lars Hyldborg Lundstrøm, Sebastian Buhl Rasmussen, Anders Kehlet Nørskov, Markus Harboe Olsen   +15 more
wiley   +1 more source

Management of Advanced Prostate Cancer in the Asia‐Pacific Region: Summary of the Asia‐Pacific Advanced Prostate Cancer Symposium 2025

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 4, Page 546-556, August 2026.
Summary of the Asia Pacific Advanced Prostate Cancer Symposium 2025, showing disciplines and diversity of participants, discussion topics (high‐risk localized/locally advanced prostate cancer; PSA persistence and recurrence; radioligand therapy; genetics and genomics; bone protection and other aspects of supportive care), key themes, and high‐level ...
Edmund Chiong, Renu Eapen, Nicholas Buchan, Kenneth Chen, Lukman Hakim, Agus Rizal Hamid, Jae‐Young Joung, Ravindran Kanesvaran, Makarand Khochikar, Jason Letran, Bannakij Lojanapiwat, Indranil Mallick, Chi Fai Ng, Pei Ing Ngam, Teng Aik Ong, Jacob Pang, Darren M. C. Poon, Natasha Roberts, Marniza Saad, Shinichi Sakamoto, Jeremy Tey, Sue Ping Thang, Poh Choo Toh, Levent Türkeri, Nguyễn Tuấn Vinh, Alvin Wong, Yao Zhu, ANZUP Cancer Trials Group, Ian D. Davis   +28 more
wiley   +1 more source

FOXA1 is a highly sensitive diagnostic marker for prostate cancer including small cell carcinoma of the prostate

Histopathology, Volume 89, Issue 2, Page 240-250, August 2026.
FOXA1 is a highly sensitive diagnostic marker for prostate cancer. Besides prostatic adenocarcinoma, it is also expressed in 57%–80% of metastatic or primary prostatic small cell carcinomas, which lose traditional prostatic markers including NKX3.1. Although it is less specific than NKX3.1, it can serve as a valuable adjunct for confirming prostatic ...
Jianping Zhao, Jun Yao, Hossein Hosseini, Ezra Baraban, Ruihe Lin, Charles C. Guo, Lei Huo, Wei Lu, Khaja Khan, Shufang Wang, Luisa Maren Solis Soto, Qingqing Ding   +11 more
wiley   +1 more source

Comparing the effectiveness of prostate cancer screening protocols: European Association of Urology– and European Randomized Study of Screening for Prostate Cancer–based strategies

International Journal of Cancer, Volume 159, Issue 2, Page 432-439, 15 July 2026.
What's new? Although screening reduces prostate cancer mortality, concerns about overdiagnosis and unnecessary biopsies have given rise to more tailored strategies. The European Association of Urology (EAU) proposed a risk‐adapted screening strategy combining prostate‐specific antigen (PSA)‐based intervals, a risk calculator, and magnetic resonance ...
Zhenwei Yang, Luuk A. van Duuren, Monique J. Roobol, Nicole S. Erler, Dimitris Rizopoulos, Eveline A. M. Heijnsdijk   +5 more
wiley   +1 more source